Page 83 - IngresoDr.MtzLanao

J, Kay R, Hamm A, Gupta A, Bachet JB, El Hariry I (2020). Erythrocyte-encapsulated asparaginase
(eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic
cancer: An open-label, randomized Phase IIb trial. Eur J Cancer., 124: 91-101.

Han HJ, Nwagwu C, Anyim O, Ekweremadu C, Kim S (2021). COVID-19 and cancer: From basic
mechanisms to vaccine development using nanotechnology. Int Immunopharmacol., 90:
107247.

Hayasi Y (2018). Determining the Influence of Granule Size on Simulation Parameters and
Residual Shear Stress Distribution in Tablets by Combining the Finite Element Method into the
Design of Experiments. Chem Pharm Bull., 66(5): 541-547.

Helal NA, Elnoweam O, Eassa HA, Amer AM, Eltokhy MA, Helal MA, Fayyaz HA, Nounou MI
(2019). Integrated continuous manufacturing in pharmaceutical industry: current evolutionary
steps toward revolutionary future. Pharm Pat Anal., 8(4): 139-161.

Hence AM (1902). Solubility of compressed tablets. Am J.Pharm., 74: 80-83.

Herrero EP, Alonso MJ, Csaba N (2012). Polymer-based oral peptide nanomedicines. Ther Deliv.,
3(5):657-68.

Higuchi WI, Bernardo PD, Metha SC (1967). Polymophism and drug availability. Dissolution rate
behavior of the polymorphic forms of sulphatiazole and methyl-prednisolone. J Pharm Sci., 56:
200-207.

Higuchi WI (1967). Diffusional models useful in biopharmaceutics. Drug release rate processes.
J Pharm Sci., 56: 315-324.

Hofsäss MA, Dressman JB (2019). The Discriminatory Power of the BCS-Based Biowaiver: A
Retrospective With Focus on Essential Medicines. J Pharm Sci., 108(9): 2824-2837.

Homer D, Small A (1977). A unified theory for estimation of cardiac output, volumes of
distribution and renal clearance from indicator dilution curves. J Theor Biol., 64(3): 535–550.

Hua M, Wu D, Wu S, Ma Y, Alsaid Y, He X (2021). 4D Printable Tough and Thermoresponsive
Hydrogels. ACS Appl Mater Interfaces., 13(11): 12689-12697.

Hull CW. Apparatus for production of three-dmensonal objects by stereo thography. US Patent.
4,575,330. March. 11. 1986.

ICH Q8. Harmonised Tripartite Guideline. Pharmaceutical Development. November. 2005.

ICH Q8(R2). Harmonised Tripartite Guideline. Pharmaceutical Development. November. 2009.

ICH Q9. Harmonised Tripartite Guideline. Quality-Risk Management. November. 2005.

ICH Q10. Harmonised Tripartite Guideline. Pharmaceutical Quality. June. 2008.

ICH Q11. Development and Manufacture of Drug Substances-Chemical and
Biotechnological/Biological Entities. July. 2013.

ICH Q12. Technical and regulatory considerations for pharmaceutical product lifecycle
management. November. 2019

81